By: Vall d’Hebron Institute of Oncology From: medicalxpress.com One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d’Hebron Institute of Oncology’s (VHIO) Growth Factors Group, in collaboration with researchers of the Cancer Research Program of Hospital del Mar Research Institute (HMRI), Barcelona, have …
Savvy Cooperative: Post-menopausal women between the ages of 46-70 diagnosed with HER2- metastatic breast cancer within the past 5 years
SCREENER SCOPE We need post-menopausal women between the ages of 46-70 diagnosed with HER2- metastatic breast cancer within the past 5 years Eligibility Criteria: Adult who has been diagnosed with breast cancer NOTE: Only patients with verified diagnoses will be considered Have been diagnosed with HER2 – metastatic breast cancer in the last five (5) years Have previously taken a …
Clinical Trials Remain Underway for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
From: targetedonc.com Ian E. Krop, MD, PhD, discusses the importance of clinical trials further exploring the role of trastuzumab deruxtecan following the FDA’s approval of the agent as treatment of patients with HER2-positive metastatic breast cancer. Ian E. Krop, MD, PhD, an associate professor of medicine with Harvard Medical School; associate chief, Division of Breast Oncology with Susan F. Smith …